NCT04322617View on ClinicalTrials.gov

Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

March 24, 2020

Primary Completion Date

March 24, 2028

Study Completion Date

March 24, 2029

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Anlotinib plus the same Immune Checkpoint Inhibitors.

Anlotinib, 8mg po qd, D1-D14 every 21days.

DRUG

Anlotinib plus the new Immune Checkpoint Inhibitors.

Anlotinib, 8mg po qd, D1-D14 every 21days.

DRUG

Anlotinib

Anlotinib, 8mg po qd, D1-D14 every 21days.

Trial Locations (1)

410013

RECRUITING

Yongchang Zhang, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER